ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Robert T Naismith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.